The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its members to speak on the record, as it ramps up the campaign against paying back over 23% on sales of branded drugs.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Ascendis, GSK, Immunitybio, Kura, Kyowa Kirin, Mabwell, Moderna, Zealand.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Bluebird, Checkpoint, Eli Lilly, Fortress, Grünenthal, Nurix, Sanofi, Simris.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Actuate, In8bio, Kalvista, Kymera, Lyra, Nervgen, Novartis, Opus Genetics, Pharvaris, Regeneron, Replimune, Reviva, Teva, Viatris, Vera, Verastem, Xilio.
New hires and promotions in the biopharma industry, including: Aravax, Catalyst, Curogen, Fate, Instil Bio, Latus Bio, Scholar Rock, Seismic, Stratus, Sutro, Tela Bio, Vectory.
Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual glucagon-like peptide 1 (GLP-1)/gastric inhibitory polypeptide (GIP) receptor agonist, HS-20094, for up to $2 billion.
Privately held Beckley Psytech Ltd. is to be taken over by Atai Life Sciences in an all-share deal that values the U.K. psychedelic drug specialist at $370 million. After making a $50 million investment in January 2024, Berlin-based Atai already owns 36% of Beckley. It will now issue 105 million new shares to its fellow Beckley investors, giving them 34% ownership of the merged company.
With a 42% placebo-adjusted reduction in proteinuria at week 36, Vera Therapeutics Inc. met its primary endpoint in the Origin phase III trial with BAFF and APRIL dual inhibitor atacicept in treating immunoglobulin A nephropathy (IgAN) in adults.
RSS
